006280 — GC Biopharma Share News
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩2tn
Brief: Gc Biopharma Corp 006280.Ks - Q1 Operating. Profit 11.7 Billion Won, Up 46% Y/Y
Brief: Green Cross Corp Q3 Operating Profit 29.2 Billion Won, Down 26.3% From Year Earlier
Brief: GC Biopharma gets CMO rights for shingles vaccine from Curevo Vaccine
Brief: Gc Biopharma Receives Marketing Authorization For Barycela In Vietnam
Brief: Green Cross Corp Q1 Operating Profit 8 Billion Won, Swings To Profit From Year Earlier
Brief: Green Cross Corp To Acquire 138 Billion Won Worth Of Shares And 100% Stake In U.S.-Based ABO Holdings Inc
Brief: GC Biopharma Launches ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid For Adults, An Immune Globulin For The Treatment Of Primary Humoral Immunodeficiency (PI) - Now Available In The US Marketplace
Brief: Green Cross Corp Wins 85 Billion Won Order
Brief: Green Cross Corp Q2 Operating Profit 17.6 Billion Won, Down 25.5% From Year Earlier
Brief: Green Cross Corp Wins 85.4 Billion Won Order
Brief: Green Cross Corp Q1 Operating Loss 15 Billion Won
Brief: Gc Cell's AB-201 Cancer Treatment To Begin Phase 1 Trials Using Lunit Ai Platform
Brief: Green Cross Corp Receives Market Approval For ‘Alyglo,’ Used For Treating Primary Humoral Immunodeficiency, From The U.S. Food And Drug Administration
Brief: Green Cross Corp Q3 Operating Profit 33 Billion Won, Down 33% From Year Earlier
Brief: Green Cross Corp Wins 200 Billion Won Order
Brief: Green Cross Corp Wins 51.6 Billion Won Order
Brief: GC Biopharma Says Signs Agreement With Catalyst Biosciences For The Acquisition Of Rare Disease Pipeline In Hematology
Brief: Mirum Pharmaceuticals & GC Pharma Enter Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea
GC Pharma says picked to import and distribute 40 mln doses of Moderna's vaccine in S.Korea